RxDoctor Payments DataLook up a doctor →

Michael Bloch, MD

Internal Medicine · Reno, NVNPI 1508970195

Payments from drug & device makers

$669,588in general payments, 2019–2025

Across 563 payments — averaging $1189.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$187K
  • Amgen$167K
  • Johnson & Johnson$105K
  • Recor Medical Inc$82K
  • Idorsia Pharmaceuticals US Inc$33K
  • Esperion Therapeutics, Inc.$29K
  • plus $67K from 13 others

What the payments were for

  • Consulting fees$122,73526%
  • Speaking & faculty fees$246,96652%
  • Travel & lodging$94,29820%
  • Food & beverage$10,9252%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669,588 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$57,152
Medicare patients
314
Services billed
913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab145$174,044
XareltoRivaroxaban112$96,306
EliquisApixaban63$75,119
Praluent PenAlirocumab44$43,281
JardianceEmpagliflozin23$28,886
NexlizetBempedoic Acid/Ezetimibe22$20,971
TrulicityDulaglutide15$20,182
MounjaroTirzepatide11$15,774
NexletolBempedoic Acid18$14,013
Icosapent Ethyl14$6,154
Ezetimibe125$2,908
Rosuvastatin Calcium149$1,890
Telmisartan51$1,821
Atorvastatin Calcium109$1,765
Warfarin Sodium104$1,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$104,712$96,306112 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$29,449$34,98440 claims
Boehringer IngelheimJardiance$747$28,88623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →